clarithromycin has been researched along with Left Ventricular Dysfunction in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirata, Y; Hishikari, K; Isobe, M; Masumura, M; Nagai, R; Nagashima, A; Nakajima, T; Ogawa, M; Suzuki, J; Takayama, K; Watanabe, R | 1 |
1 other study(ies) available for clarithromycin and Left Ventricular Dysfunction
| Article | Year |
|---|---|
Clarithromycin attenuates myocardial ischemia-reperfusion injury.
Topics: Animals; Clarithromycin; Fibrosis; Macrophages; Male; Matrix Metalloproteinase Inhibitors; Myocardial Infarction; Myocardial Reperfusion Injury; Protein Synthesis Inhibitors; Rats; Rats, Sprague-Dawley; Ventricular Dysfunction, Left | 2010 |